ISSN 1214-0287 (on-line), ISSN 1214-021X (printed)
J Appl Biomed
Volume 11 (2013), No 2, p 71-78
DOI 10.2478/v10136-012-0024-9

Circadian variation in hematological toxicity of the immunosuppressive agent "Mycophenolate Mofetil" in rats

Ichrak Dridi, Wafa Ben-Cherif, Karim Aouam, Mohsen Hassine, Mossadok Ben-Attia, Alain Reinberg, Naceur Abderrazak Boughattas

Address: Ichrak Dridi, Laboratory of Pharmacology, Faculty of Medecine, University of Monastir, 5019 Monastir, Tunisia
dridi.ichrak@yahoo.fr

Received 12th September 2012.
Revised 6th November 2012.
Published online 8th November 2012.

Full text article (pdf)
Full text article (html)

SUMMARY
Because of biological rhythms, drug efficiency and toxicity vary according to the time of administration of the drug. This study investigates whether the haematological toxicity of the immunosuppressive agent Mycophenolate Mofetil varies according to the circadian dosing-time in rats. 300 mg/kg of Mycophenolate Mofetil was injected by i.p. route to different groups of animals at six different circadian stages (1, 7, 13, and 19 Hours After Light Onset, HALO). Mycophenolate Mofetil treatment induced a significant decrease at 7 HALO in red blood cells (-18%), in haemoglobin rate (-15%) and in white blood cells (-54%). These parameters followed a circadian rhythm with an acrophase located at the end of the light-rest phase. A significant thrombocytopenia was observed according to MMF the circadian dosing-time. In the controls, the number of platelets followed a circadian rhythm. Mycophenolate Mofetil modified this rhythm which became an 8-h ultradian rhythm. The data indicate that, the Mycophenolate Mofetil-induced haematological toxicity was maximum when the drug was administered in the middle of the light-rest phase, which is physiologically analogous to the end of the activity of the diurnal phase in human patients.

KEY WORDS
circadian rhythm; immunosuppressive agent; MMF; hematological toxicity; rat

REFERENCES
Ben-Cherif W, Dridi I, Aouam K, Ben-Attia M, Reinberg A. Chronotolerance study of the antiepileptic drug valproic acid in mice. J Circadian Rhythms. 10: 3, 2012.
[CrossRef] [PubMed]

Berger J. The age of biomedicine: current trends in traditional subjects. J Appl Biomed. 9: 57-61, 2011.
[CrossRef] [JAB]

Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 34: 429-455, 1998.
[CrossRef] [PubMed]

Cantarovich M, Brown NW, Ensom MH, Jain A, Kuypers DR, Van Gelder T, Tredger JM. Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplant Rev. 25: 65-77, 2011.
[CrossRef] [PubMed]

Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc. 36: 703-704, 2004.
[CrossRef] [PubMed]

Danesi R, Mosca M, Boggi U, Mosca F, Del Tacca M. Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today. 6: 475-482, 2000.
[CrossRef]

Dridi I, Ben-Cherif W, Aouam K, Ben-Attia M, Reinberg A, Boughattas NA. Murine circadian time-dependent tolerance to the immunosuppressive agent mycophenolate mofetil (MMF). Biol Rhythm Res. 1-9, 2012.
[CrossRef]

EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.1. Anaemia. Nephrol Dial Transplant. 17: 48, 2002a.

EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Leukopenia. Nephrol Dial Transplant. 17: 49, 2002b.
[CrossRef]

Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci. 685: 309-329, 1993.
[CrossRef] [PubMed]

Halberg F. Chronobiology. Annu Rev Physiol. 31. 675-725, 1969.
[CrossRef] [PubMed]

Haus E. Biologic rhythms in hematology. Pathol Biol. 44: 618-630, 1996.
[PubMed]

Haus E, Smolensky MH. Biologic rhythms in the immune system. Chronobiol Int. 16: 581-622, 1999.
[CrossRef] [PubMed]

Haus E, Lakatua DJ, Swoyer J, Sackett-Lundeen L. Chronobiology in hematology and immunology. Am J Anat. 168: 467-517, 1983.
[CrossRef] [PubMed]

Khedhaier A, Ben-Attia M, Gadacha W, Sani M, Bouzouita K, Chouchane L, Mechkouri M, Reinberg A, Boughattas NA. Circadian Rhythms in Toxic Effects of the Serotonin Antagonist Ondansetron in Mice. Chronobiol Int. 20: 1103-1116, 2003.
[CrossRef] [PubMed]

Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther. 12: R208, 2010.
[CrossRef] [PubMed]

Mackie F, Verran D, Horvath J, Tiller D. Severe thrombocytopenia with OKT3 use for steroid-resistant rejection in a cadaveric renal transplant recipient. Nephrol Dial Transplant. 11: 2378, 1996.
[CrossRef] [PubMed]

Nelson W, Tong YL, Lee JK, Halberg F. Methods for cosinor-rhythmometry. Chronobiologia. 6: 305-323, 1979.
[PubMed]

Neumann I, Haidinger M, Jager H, Grutzmacher H, Griesmacher A, Muller MM, Bayer PM, Meisl FT. Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients. J Am Soc Nephrol. 14: 721-727, 2003.
[CrossRef] [PubMed]

Ohkura K, Uto Y, Nagasawa H, Hori H. Effect of molecular chirality and side chain bulkiness on angiogenesis of haloacetylcarbamoyl-2-nitroimidazole compounds. Anticancer Res. 27: 3693-3700, 2007a.
[PubMed]

Ohkura N, Oishi K, Sekine Y, Atsumi G, Ishida N, Matsuda J, Horie S. Comparative Study of Circadian Variation in Numbers of Peripheral Blood Cells among Mouse Strains: Unique Feature of C3H/HeN Mice. Biol Pharm Bull. 30: 1177-1180, 2007b.
[CrossRef] [PubMed]

Ottaway CA, Husband AJ. The influence of neuroendocrine pathways on lymphocyte migration. Immunol Today. 15: 511-517, 1994.
[CrossRef]

Pally C, Tanner M, Rizvi H, Papageorgiou C, Schuurman HJ. Tolerability profile of sodium mycophenolate (ERL080) and mycophenolate mofetil with and without cyclosporine (Neoral) in the rat. Toxicology. 157: 207-215, 2001.
[CrossRef]

Piccione G, Fazio F, Giudice E, Grasso F, Morgante M. Nycthemeral change of some haematological parameters in horses. J Appl Biomed. 3: 123-128, 2005.
[JAB]

Reinberg AE. Concepts in chronopharmacology. Annu Rev Pharmacol Toxicol. 32: 51-66, 1992.
[CrossRef] [PubMed]

Sani M, Sebai H, Boughattas NA, Ben-Attia M. Time-of-day dependence of neurological deficits induced by sodium nitroprusside in young mice. J Circadian Rhythms. 9: 5, 2011.
[CrossRef] [PubMed]

Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. The US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 60: 225-232, 1995.
[CrossRef] [PubMed]

Tsutsumi H, Monnai Y, Ishii H, Tanioka Y, Tanigawa M. Diurnal variation and effects of fasting on blood constituent in minipigs. Exp Anim. 48: 247-254, 1999.
[CrossRef] [PubMed]

Virji M, Carter JE, Lirenman DS. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant. 5: 293-296, 2001.
[CrossRef] [PubMed]

Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonhoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 13: 759, 2002.
[PubMed]
CITED

0


BACK